ライフサイエンスコーパス: thyroid carcinoma

1 ular targets for therapeutic intervention in thyroid carcinoma.

2 verexpressed in many cancer types, including thyroid carcinoma.

3 ioiodide imaging and therapeutic ablation of thyroid carcinoma.

4 Of the 93 patients, 57 (61%) had papillary thyroid carcinoma.

5 by 131I therapy for papillary and follicular thyroid carcinoma.

6 ed in multiple cancers, including follicular thyroid carcinoma.

7 nts after a thyroidectomy for differentiated thyroid carcinoma.

8 near-total thyroidectomy for differentiated thyroid carcinoma.

9 icacy of sorafenib in patients with advanced thyroid carcinoma.

10 anscription factors have not been studied in thyroid carcinoma.

11 asia types 2A and 2B, and familial medullary thyroid carcinoma.

12 ites of distant metastasis in differentiated thyroid carcinoma.

13 ive RET mutant, RET/PTC1, found in papillary thyroid carcinoma.

14 for the metastatic progression of papillary thyroid carcinoma.

15 mutation is frequently detected in papillary thyroid carcinoma.

16 th the risk of developing sporadic medullary thyroid carcinoma.

17 oto-oncogene could prevent or cure medullary thyroid carcinoma.

18 major weapon in the fight against metastatic thyroid carcinoma.

19 2A (MEN-2A) or type 2B or familial medullary thyroid carcinoma.

20 efficacy of 131I therapy for differentiated thyroid carcinoma.

21 ging evidence of lung cancer; 3 had renal or thyroid carcinoma.

22 nt of suspected recurrence of differentiated thyroid carcinoma.

23 the mass suggested a diagnosis of papillary thyroid carcinoma.

24 y to illustrate the evolutionary features of thyroid carcinoma.

25 be useful in the diagnosis and treatment of thyroid carcinoma.

26 no effective treatment exists for anaplastic thyroid carcinoma.

27 rcinoma, follicular carcinoma, and medullary thyroid carcinoma.

28 e metastases in patients with differentiated thyroid carcinoma.

29 actor, erythroid 2 like 2 (NFE2L2) fusion in thyroid carcinoma.

30 rrangements found in radio-induced papillary thyroid carcinoma.

31 is an extremely rare condition in papillary thyroid carcinoma.

32 virtually all of them will develop medullary thyroid carcinoma.

33 stomach carcinoma, and thyroglobulin (TG) in thyroid carcinoma.

34 dine therapy in patients with differentiated thyroid carcinoma.

35 TT cell line, derived from a human medullary thyroid carcinoma.

36 CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.

37 linical promise in the treatment of advanced thyroid carcinoma.

38 hyperplasia progresses slowly to follicular thyroid carcinoma.

39 genic RAS mutations are present in 15-30% of thyroid carcinomas.

40 ied and overexpressed in papillary renal and thyroid carcinomas.

41 lymphocytic and myeloblastic leukemias, and thyroid carcinomas.

42 re one of the genetic hallmarks of papillary thyroid carcinomas.

43 cluding those derived from breast, colon and thyroid carcinomas.

44 pituitary anterior lobe tumors and medullary thyroid carcinomas.

45 T tyrosine kinase commonly seen in papillary thyroid carcinomas.

46 d to be tumor-initiating events in papillary thyroid carcinomas.

47 lasms, including colon, breast, ovarian, and thyroid carcinomas.

48 ly regulate Apo2L/TRAIL-induced apoptosis in thyroid carcinomas.

49 T proto-oncogene detected in human papillary thyroid carcinomas.

50 ET/PTC3Fhit-/- mice did not develop advanced thyroid carcinomas.

51 fferent somatic mutations (23%) in papillary thyroid carcinomas.

52 mice promotes anaplasia and invasiveness of thyroid carcinomas.

53 quently found in radiation-induced papillary thyroid carcinomas.

54 e the most common type counting 86.4% of all thyroid carcinomas.

55 e performed on 148 consecutive patients with thyroid carcinoma (125 papillary, 2 follicular, 8 Hurthl

56 Molecular profiles of 11 papillary thyroid carcinomas, 13 follicular variant of papillary t

57 dullary thyroid tumors (55 FA, 27 follicular thyroid carcinomas, 35 papillary thyroid carcinomas, and

58 6%), lung squamous cell carcinoma (2.3%) and thyroid carcinoma (8.7%), suggesting a potential for app

59 ly mutated malignant subtypes were medullary thyroid carcinoma (9/12, 75%) and PTC (14/30, 47%).

60 rcinomas, 13 follicular variant of papillary thyroid carcinomas, 9 follicular thyroid carcinomas, and

61 position syndrome characterized by medullary thyroid carcinoma, a tumour of the calcitonin-producing

62 Medullary thyroid carcinoma accounts for 2% to 5% of thyroid malig

63 a 7-d period in 15 patients with metastatic thyroid carcinoma after administration of (124)I-NaI.

64 oped in a patient with metastatic anaplastic thyroid carcinoma after an extraordinary 18-month respon

65 hemical evidence of recurrent differentiated thyroid carcinoma and a tumor-negative neck US, the high

66 ssion and the oncogenic activation of RET in thyroid carcinoma and describe the involved signal trans

67 V/PV) mice) spontaneously develop follicular thyroid carcinoma and distant metastases similar to huma

68 and neck squamous cell carcinoma, melanoma, thyroid carcinoma and endometrial carcinoma).

69 ous melanomas, cutaneous nevi, and papillary thyroid carcinoma and in a small fraction of other cance

70 ter understanding of the correlation between thyroid carcinoma and LFS, tumor profile data of Brazili

71 n human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A a

72 52 PTCs, respectively, but not in follicular thyroid carcinoma and normal thyroid tissue.

73 N 2 syndromes are characterized by medullary thyroid carcinoma and other endocrinopathies.

74 The review focuses first on medullary thyroid carcinoma and performing prophylactic thyroidect

75 he increased expression of CAIX in medullary thyroid carcinoma and provide a rationale for therapy si

76 el CREB3L2-PPARgamma gene fusion mutation in thyroid carcinoma and reveal a thyroid signaling pathway

77 y generated a transgenic mouse model of PPFP thyroid carcinoma and showed that feeding the PPARgamma

78 ified as a gene fused to the ret oncogene in thyroid carcinoma and subsequently as a co-activator for

79 ributions of mtDNA sequence variants between thyroid carcinomas and controls.

80 ere found in follicular variant of papillary thyroid carcinomas and follicular adenomas.

81 We characterized CSCs in thyroid carcinomas and generated clones of CSC lines.

82 n which is frequently expressed in papillary thyroid carcinomas and has been detected in thyroid tiss

83 overexpressed in many cancer types including thyroid carcinomas and has well established roles in tum

84 tein, not only in FTCs but also in papillary thyroid carcinomas and Hurthle cell carcinomas.

85 in hairy-cell leukemia, cutaneous melanoma, thyroid carcinomas and, less commonly, in ovarian, colon

86 econdary breast carcinoma, 15% for secondary thyroid carcinoma, and 13% for secondary soft-tissue sar

87 e pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not di

88 follicular thyroid carcinomas, 35 papillary thyroid carcinomas, and 22 undifferentiated thyroid carc

89 f papillary thyroid carcinomas, 9 follicular thyroid carcinomas, and 26 benign tumors (follicular ade

90 SNAI1 and SNAI2 are ectopically expressed in thyroid carcinomas, and aberrant expression in mice is a

91 ncogene, which is common in human follicular thyroid carcinomas appears to act via dominant negative

92 Thyroid carcinomas are fairly uncommon and include disea

93 Thyroid carcinomas are known to harbor oncogenic driver

94 Differentiated thyroid carcinomas are the most frequent endocrine neopl

95 to the widely prevalent well-differentiated thyroid carcinomas are unclear.

96 been implicated in pathogenesis of papillary thyroid carcinoma as a fusion partner of RET.

97 In thyroid carcinomas as a group, nuclear PTEN immunostaini

98 (SPECT/CT) on nodal staging of patients with thyroid carcinoma at the first ablative radioiodine ther

99 roteasome inhibitor bortezomib on anaplastic thyroid carcinoma (ATC) characterized by complete refrac

100 Anaplastic thyroid carcinoma (ATC) has among the worst prognoses of

101 Anaplastic thyroid carcinoma (ATC) is a frequently lethal malignanc

102 Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of t

103 Anaplastic thyroid carcinoma (ATC) is one of the most lethal malign

104 ion is approximately 0.8 nM while anaplastic thyroid carcinoma (ATC) tumor growth was inhibited three

105 The increase in thyroid carcinoma, attributable to the very large amount

106 patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gla

107 sensus about classification and treatment of thyroid carcinoma based on standard histopathological an

108 ith suspected recurrence from differentiated thyroid carcinoma, based on an increased thyroglobulin (

109 sed after a thyroidectomy for differentiated thyroid carcinoma because it has been reported to reduce

110 y detected BRAF mutations in human papillary thyroid carcinomas (BRAF(V600E)) in thyroid follicular c

111 3 is widely expressed in well-differentiated thyroid carcinomas, but not in normal thyrocytes and ben

112 All ret/PTC1 mice developed thyroid carcinomas, but tumors in p53-/- mice were more

113 nd samples of human follicular and papillary thyroid carcinoma by reverse transcriptase-polymerase ch

114 ment in roughly one quarter of patients with thyroid carcinoma by upstaging or downstaging their dise

115 E-Cadherin (CDH1) expression is reduced in thyroid carcinomas by primarily unknown mechanisms.

116 Although CAXII was present in all types of thyroid carcinomas, CAIX, a direct HIF target implicated

117 example, anaplastic or poorly differentiated thyroid carcinoma) carry several complex genetic alterat

118 red by FOXE1 and PTCSC2 in a human papillary thyroid carcinoma cell line (KTC-1) and unaffected thyro

119 Depletion of REGgamma in a thyroid carcinoma cell line results in cell-cycle and pr

120 essed the expression of Fas, DR4, and DR5 in thyroid carcinoma cell lines and in 31 thyroid carcinoma

121 Fas was found to be expressed in most thyroid carcinoma cell lines and tissue specimens.

122 tary tumor, breast carcinoma cell lines, and thyroid carcinoma cell lines showed that in cells expres

123 ombinant TRAIL induced apoptosis in 10 of 12 thyroid carcinoma cell lines tested, by activating caspa

124 respectively, and tested the sensitivity of thyroid carcinoma cell lines to Fas- and TRAIL-induced a

125 s-linking of Fas did not induce apoptosis in thyroid carcinoma cell lines, Fas-mediated apoptosis did

126 f migration in both papillary and follicular thyroid carcinoma cell lines.

127 g growth factor-beta1 (TGF-beta1), papillary thyroid carcinoma cells acquired increased cancer stem c

128 els for the evaluation of IDO1 expression in thyroid carcinoma cells and for the study of involved si

129 Thyroid carcinoma cells harboring activated RET/PTC, RAS

130 ssion pattern was recapitulated in medullary thyroid carcinoma cells in vivo, consistent with a growt

131 The mechanism of how IFNgamma sensitized thyroid carcinoma cells to TRAIL-induced apoptosis was i

132 regulating Apo2L/TRAIL-induced apoptosis in thyroid carcinoma cells, as well as the impact of insuli

133 d-type B-RAF melanoma cells and mutant B-RAF thyroid carcinoma cells.

134 electively kills neoplastic cells, including thyroid carcinoma cells.

135 of 96.2% (3 follicular variant of papillary thyroid carcinomas clustered with the benign lesions).

136 A subset of thyroid carcinomas contains a t(2;3)(q13;p25) chromosoma

137 mPTC has become the most common form of thyroid carcinoma detected during thyroidectomies in Chi

138 Thyroid carcinoma development was analyzed in CombitTA-S

139 Recent advances in the knowledge of thyroid carcinomas development identified receptor tyros

140 PTC and anaplastic thyroid carcinomas did not show significant down-regulat

141 In some patients with well-differentiated thyroid carcinoma, dosimetry is necessary to avoid toxic

142 at stratifying patients with differentiated thyroid carcinoma (DTC) into prognostic risk groups.

143 verall prognosis in pediatric differentiated thyroid carcinoma (DTC) is excellent.

144 g recurrence or metastases in differentiated thyroid carcinoma (DTC) patients with elevated serum thy

145 Differentiated thyroid carcinoma (DTC), as one of the major component c

146 ar mortality in patients with differentiated thyroid carcinoma (DTC).

147 t PRRX1 plays an important role in papillary thyroid carcinoma EMT and disease progression.

148 vidence of persistent or recurrent medullary thyroid carcinoma five or more years after total thyroid

149 study, we have shown that familial medullary thyroid carcinoma (FMTC) mutants RET(Y791F) and RET(S891

150 e cause MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC).

151 encies of two of the most common subtypes of thyroid carcinoma, follicular (FTC) and papillary (PTC),

152 hat 1 of 10 thyroid cancer lines [follicular thyroid carcinoma FTC-133] had hemizygous deletion and a

153 Follicular thyroid carcinoma (FTC) frequently harbors the PAX8/PPAR

154 suffering from bone metastases of follicular thyroid carcinoma (FTC) have a poor prognosis because of

155 implicated in the pathogenesis of follicular thyroid carcinoma (FTC), where a translocation with PAX8

156 llary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC).

157 (BHD-origin renal cell carcinoma UOK257 and thyroid carcinoma FTC133) but not in their folliculin ex

158 A patient with papillary thyroid carcinoma had stable disease for more than 2 yea

159 oactive iodine ((131)I) for the treatment of thyroid carcinoma has changed over the past 50 y.

160 with a wide variety of tumors; nevertheless, thyroid carcinoma has not been evaluated in this syndrom

161 to formulate a consensus about treatment of thyroid carcinoma have resulted in published guidelines

162 patients with advanced, well-differentiated thyroid carcinoma illustrate the need for dosimetry to h

163 To determine the frequency of thyroid carcinoma in Brazilian carriers of a founder TP5

164 able increase in radiation-induced papillary thyroid carcinoma in children and young adults.

165 Here, we describe a novel model of thyroid carcinoma in zebrafish that reveals temporal cha

166 rtant for the development and progression of thyroid carcinomas in genetically permissive hosts.

167 Papillary thyroid carcinomas in humans are associated with the ret

168 ions known to date detects only a portion of thyroid carcinomas in preoperative FNAs in our cohort an

169 highly expressed in cell lines derived from thyroid carcinomas, in human thyroid carcinoma samples,

170 first 20 years there was a large increase in thyroid carcinoma incidence and a possible radiation-rel

171 of aggressive and refractory human advanced thyroid carcinomas, including local invasion and metasta

172 lecular signature of advanced and metastatic thyroid carcinoma involves deregulation of multiple fund

173 Medullary thyroid carcinoma is a relatively rare tumor with poor p

174 tomy caused by local recurrence of papillary thyroid carcinoma is extremely rare.

175 Papillary thyroid carcinoma is frequently multifocal.

176 Interestingly, the prognosis of thyroid carcinoma is highly dependent on the age of the

177 Medullary thyroid carcinoma is the most common cause of death in p

178 Thyroid carcinoma is the most common endocrine malignanc

179 omic localization of recurrent or metastatic thyroid carcinoma, leading to improved diagnostic accura

180 Thyroid carcinoma may be associated with the Brazilian f

181 er thyroidectomy for papillary or follicular thyroid carcinoma may be performed using diagnostic imag

182 egies to prevent or to treat human papillary thyroid carcinomas, MEN 2 disease, as well as the sporad

183 Rb1(+/-)Nras(+/-) animals, distant medullary thyroid carcinoma metastases are associated with loss of

184 associated with the development of medullary thyroid carcinoma (MTC) and pathogenesis of multiple end

185 In patients with medullary thyroid carcinoma (MTC) and type 2A multiple endocrine n

186 Patients with hereditary medullary thyroid carcinoma (MTC) associated with multiple endocri

187 ivation of Ras or Raf in the human medullary thyroid carcinoma (MTC) cell line, TT, induces growth ar

188 All of the cases of medullary thyroid carcinoma (MTC) express the RET receptor tyrosin

189 Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer that

190 Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor mainly

191 Medullary thyroid carcinoma (MTC) is a rare endocrine tumor arisin

192 The prognosis of medullary thyroid carcinoma (MTC) varies from long- to short-term

193 contrast to the hereditary form of medullary thyroid carcinoma (MTC), little is known about the etiol

194 thus preventing the development of medullary thyroid carcinoma (MTC), the dominant endocrinopathy in

195 se 2 phenotypes is the presence of medullary thyroid carcinoma (MTC).

196 ients with biochemical evidence of medullary thyroid carcinoma (MTC).

197 atients with distant metastasis of medullary thyroid carcinoma (MTC).

198 lasia type 2 (MEN 2) that includes medullary thyroid carcinoma (MTC).

199 labeled with (111)In or (131)I in medullary thyroid carcinoma (MTC).

200 therapy for patients with advanced medullary thyroid carcinoma (MTC).

201 Medullary thyroid carcinomas (MTC), a tumor of the thyroid parafol

202 (pheochromocytomas) and malignant (medullary thyroid carcinomas, MTCs) tumors from patients with mult

203 lar thyroid adenoma (n = 10), and follicular thyroid carcinoma (n = 10) showed RASSF1A promoter hyper

204 of the two most common types of nonmedullary thyroid carcinoma, namely papillary thyroid carcinoma (P

205 For medullary thyroid carcinoma, near-total and total thyroidectomy wi

206 in a large pedigree displaying non-medullary thyroid carcinoma (NMTC).

207 Sarcomas, breast and thyroid carcinomas occurred with similar frequency and l

208 oth solid tumors (osteosarcoma and papillary thyroid carcinoma) occurred in recipients of DRZ.

209 nic activation has long been demonstrated in thyroid carcinomas of follicular cell derivation, but no

210 on group, 3 (10%) showed well-differentiated thyroid carcinoma on permanent histology.

211 cells were microinjected with the papillary thyroid carcinoma oncogene (RET/PTC1 short isoform, know

212 Arm B patients had other subtypes of thyroid carcinoma or prior chemotherapy, and did not req

213 To evaluate the characteristics of thyroid carcinoma over time, we carried out a retrospect

214 Papillary thyroid carcinoma overexpress transforming growth factor

215 redictors of poor survival in differentiated thyroid carcinomas (P =.027 and P =.007, respectively).

216 e well-defined foci of poorly differentiated thyroid carcinoma (PDTC).

217 milies were cancer affected and, among them, thyroid carcinoma presented a prevalence of 10.9% (3 men

218 A substantial increase in papillary thyroid carcinoma (PTC) among children exposed to the ra

219 xamination of the mass confirmed a papillary thyroid carcinoma (PTC) and enlarged metastatic lymph no

220 edullary thyroid carcinoma, namely papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma

221 ET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimo

222 that 63 of 110 (57%) human primary papillary thyroid carcinoma (PTC) cases expressed nuclear pY-STAT3

223 ollicular tumours resembling human papillary thyroid carcinoma (PTC) depending on the founder line ex

224 Papillary thyroid carcinoma (PTC) displays higher heritability tha

225 Papillary thyroid carcinoma (PTC) displays strong but so far large

226 Although papillary thyroid carcinoma (PTC) displays strong heritability, no

227 ients undergoing thyroidectomy for papillary thyroid carcinoma (PTC) have subclinical nodal disease a

228 Papillary thyroid carcinoma (PTC) is clinically heterogeneous.

229 Papillary thyroid carcinoma (PTC) is the most common type of thyro

230 Biomarkers of papillary thyroid carcinoma (PTC) metastasis can accurately identi

231 A genome-wide association study of papillary thyroid carcinoma (PTC) pinpointed two independent SNPs

232 Papillary thyroid carcinoma (PTC) remained to be the most common t

233 mately 40 percent of patients with papillary thyroid carcinoma (PTC) typically have either intrachrom

234 he most common somatic mutation in papillary thyroid carcinoma (PTC), how it induces tumor aggressive

235 Papillary thyroid carcinoma (PTC), the most frequent thyroid cance

236 nts, which are frequently found in papillary thyroid carcinoma (PTC).

237 at exposure and risk of developing papillary thyroid carcinoma (PTC).

238 tle is known about the genetics of papillary thyroid carcinoma (PTC).

239 those associated with a precursor papillary thyroid carcinoma (PTC).

240 13) firmly associated with risk of papillary thyroid carcinoma (PTC).

241 e factors that were induced by RET/papillary thyroid carcinoma (PTC)3 gene expression including sever

242 Genetic analysis of human papillary thyroid carcinomas (PTC) has revealed unique chromosomal

243 Most papillary thyroid carcinomas (PTC) have an isozyme-specific reduct

244 g and expression analysis of eight papillary thyroid carcinomas (PTC) to comprehensively characterize

245 s detected in approximately 45% of papillary thyroid carcinomas (PTC).

246 most common genetic alteration in papillary thyroid carcinomas (PTC).

247 st prevalent genetic alteration in papillary thyroid carcinomas (PTC).

248 of genetic alterations detected in papillary thyroid carcinomas (PTC).

249 cation and treatment selection for papillary thyroid carcinomas (PTCs) do not uniformly predict tumor

250 Papillary thyroid carcinomas (PTCs) that invade into local structu

251 various thyroid neoplasms such as papillary thyroid carcinomas (PTCs), follicular thyroid adenomas a

252 st-thyroidectomy patients for differentiated thyroid carcinoma received a 185-MBq (5 mCi) diagnostic

253 oidectomies in China while other features of thyroid carcinoma remained similarly in the recent years

254 t common endocrine malignancy, and papillary thyroid carcinoma represents the most common thyroid can

255 ation of the RET proto-oncogene in papillary thyroid carcinomas results from rearrangements linking t

256 the rearranged during transfection/papillary thyroid carcinoma (RET/PTC) fusion oncogene family durin

257 es derived from thyroid carcinomas, in human thyroid carcinoma samples, and their metastases.

258 V/PV) mice) spontaneously develop follicular thyroid carcinoma similar to human cancer.

259 model that spontaneously develops follicular thyroid carcinoma similar to human thyroid cancer (Thrb(

260 se) that spontaneously develops a follicular thyroid carcinoma similar to human thyroid cancer.

261 /PV) mouse) spontaneously develop follicular thyroid carcinoma similar to human thyroid cancer.

262 or more SMNs, including four leukemias, five thyroid carcinomas, six breast carcinomas, and four sarc

263 R5 in thyroid carcinoma cell lines and in 31 thyroid carcinoma specimens by Western blot analysis and

264 lymorphism followed by DNA sequencing in 125 thyroid carcinoma specimens from 107 patients, to includ

265 possible role of ras genotyping to identify thyroid carcinoma subsets associated with poor prognosis

266 initiate distinct pathways of oncogenesis in thyroid carcinoma subtypes.

267 mas, and its expression pattern in medullary thyroid carcinomas suggested contribution of both hypoxi

268 noncoding RNA gene (lincRNA) named Papillary Thyroid Carcinoma Susceptibility Candidate 3 (PTCSC3) lo

269 Thyroid carcinomas that harbor RET/PTC oncogenes are wel

270 Papillary thyroid carcinomas that invade locally or metastasize ar

271 d expression of ret/PTC1 developed papillary thyroid carcinomas that were minimally invasive and did

272 Combi-TA mice developed papillary thyroid carcinomas, the incidence of which was increased

273 correlated with the generation of papillary thyroid carcinomas, the most prevalent malignancy of the

274 overall frequency of 2.9% and included three thyroid carcinomas, three carcinoids of the small bowel,

275 tatic lesions of a mouse model of follicular thyroid carcinoma [thyroid hormone beta receptor (TRbeta

276 n insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four norm

277 hyroid tumors of a mouse model of follicular thyroid carcinoma (TRbeta(PV/PV) mice).

278 arcinogenesis in a mouse model of follicular thyroid carcinoma (TRbetaPV/PV mouse).

279 ation of mutated RET gene in human medullary thyroid carcinoma TT cells.

280 We conclude that papillary thyroid carcinoma tumor cells exhibit increased cancer s

281 lder; total thyroidectomy for differentiated thyroid carcinoma; tumor-node-metastasis (TNM) stage, as

282 thyroid carcinomas, and 22 undifferentiated thyroid carcinomas) using immunohistochemistry and corre

283 eatment of patients with well-differentiated thyroid carcinoma; usual amounts vary widely.

284 o underwent thyroidectomy for differentiated thyroid carcinoma was performed.

285 , follicular thyroid adenoma, and follicular thyroid carcinoma was quantified.

286 Among patients with differentiated thyroid carcinomas (WDC and PDC), 11 (55.0%) of 20 patie

287 st common other cancers in the patients with thyroid carcinoma were breast cancer (5 patients) and so

288 y following thyroidectomy for differentiated thyroid carcinoma were enrolled, along with their 65 hou

289 k thyroid tissues of patients with papillary thyroid carcinoma were quantified.

290 ere associated with follicular and papillary thyroid carcinomas, whereas long telomeres and low level

291 We report a case of papillary thyroid carcinoma which invades IJV with hypervascular t

292 he tumour cells of a patient with follicular thyroid carcinoma, which affects the binding of the tumo

293 tation carriers have renal cell or papillary thyroid carcinomas, which are also CS-related features.

294 to maintain the colony developed anaplastic thyroid carcinoma with liver metastases.

295 ged, they spontaneously developed follicular thyroid carcinoma with pathological progression from hyp

296 a novel CREB3L2-PPARgamma fusion mutation in thyroid carcinoma with t(3;7)(p25;q34), showing that a f

297 needs to be to achieve long-term control of thyroid carcinoma with tracheal invasion.

298 e redifferentiation in poorly differentiated thyroid carcinomas with constitutive activation of eithe

299 patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate

300 t also promotes the development of medullary thyroid carcinomas yielding metastases at a high frequen